U.S. unveils coordinated plan to combat antimicrobial resistance
U.S. task force unveils coordinated government plan to combat antimicrobial resistance
An interagency task force has mapped the government's response to the rising threat of antimicrobial resistance (AR), including implementation of "appropriate" antibiotic use policies. "Unless AR problems are detected as they emergeand actions are taken quickly to contain themthe world may be soon faced with previously treatable diseases that have again become untreatable, as in the pre-antibiotic era," said the federal panel in releasing a 44-page public health action plan.
That pre-antibiotic era ended in the 1940s with the widespread availability of penicillin and the discovery of streptomycin. But scientists and clinicians fear it may be returning with several microbes rapidly becoming drug-resistant, such as those that cause pneumonia, ear infections, and meningitis (e.g., Streptococcus pneumoniae); skin, bone, lung, and bloodstream infections (e.g., Staphylococcus aureus); food-borne infections (e.g., Escherichia coli); and infections transmitted in health-care settings (e.g., enterococci and Klebsiella).
The four major components of the plansurveillance, prevention and control, research, and product developmentare broken down into 84 action items. Thirteen considered "essential" to addressing the problem were assigned the highest priority. The plan will be implemented incrementally as resources become available. The overall goal is to:
Concerning appropriate prescription drug use, the task force plans a public health education program as a national priority. Inappropriate prescribing will be targeted by developing clinical guidelines and computer-assisted decision support. The hope is to extend the useful life of antimicrobial Rxs. Research is needed to determine if variations in regimens foster or reduce AR emergence and spread, the report said. The relationship between prescribing behavior and marketing practices for specific antibiotics also will be evaluated.
"Infection control in health settings will be enhanced by developing new interventions based on rapid diagnosis, improved understanding of factors that promote cross-infection, and modified medical devices or procedures that reduce the risk of infection," the report continued. New classes of antibiotics are needed to kill resistant organisms, and so are new vaccines and anti-infective devices. The report said financial or investment incentives may be needed to spur development of the new products.
Mike Conlan. U.S. task force unveils government plan to combat antimicrobial resistance. Drug Topics 2001;3:16.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.